Skin CancerAdvanced · 10 min read

Penile Intraepithelial Neoplasia (PeIN)

Mucosal in-situ SCC of the penis. HPV-driven and HPV-independent pathways with distinct clinical and dermoscopic signatures.

By Dr. Yehonatan KaplanPublished Updated

In brief

Penile intraepithelial neoplasia is the histopathological precursor to invasive penile squamous cell carcinoma. It comprises three classical clinical variants (Bowenoid papulosis, Bowen disease of the penis, erythroplasia of Queyrat) that are morphologically distinct on dermoscopy yet share a common in-situ histology. The 2022 WHO classification reorganized penile carcinomas and their precursors along etiologic lines, separating HPV-associated lesions (basaloid, warty, mixed warty-basaloid) from HPV-independent disease (differentiated PeIN, often arising on a background of lichen sclerosus). Risk of progression to invasive disease can reach 30 percent, so early recognition and biopsy site selection are clinically important. Dermoscopy in this anatomic location is dominated by an orange-pink mucosal background, prominent clustered dotted and glomerular vessels, structureless areas, and absence of a true pigment network. p16(INK4a) immunohistochemistry remains the cornerstone of HPV surrogate testing and now carries clear prognostic weight.

Clinical content

01PeIN is in-situ squamous cell carcinoma confined to the penile epithelium. Three clinically distinct variants account for most cases: Bowenoid papulosis (multiple red-brown verrucous papules on younger men, mean age in the 30s to late 50s, usually shaft), Bowen disease of the penis (solitary scaly pink to red plaque on the keratinized shaft, prepuce, or glans, typically older men), and erythroplasia of Queyrat (well-defined, bright red, moist or velvety plaque on the mucosal glans or visceral prepuce). Histopathologically these variants may be indistinguishable.

02The 2022 WHO Classification of Penile and Scrotal Cancers (Menon et al., Histopathology 2022; Moch et al., Eur Urol 2022) restructured the disease around HPV status. Squamous precursors are now classified as HPV-associated PeIN (subdivided into basaloid, warty, and mixed warty-basaloid) and HPV-independent PeIN (the differentiated subtype, classically arising in lichen sclerosus). The corresponding invasive carcinomas follow the same dichotomy. The 2023 EAU-ASCO collaborative guideline made p16(INK4a) immunohistochemistry reporting mandatory for any penile SCC pathology report.

03HPV-associated and HPV-independent pathways differ at the molecular level. High-risk HPV 16 dominates (46 to 62 percent of HPV-positive cases), with HPV 18 less common. E6 degrades p53 and E7 inactivates Rb, releasing p16(INK4a) from negative feedback so that the protein accumulates. p16 overexpression by IHC is therefore the standard surrogate for transcriptionally active HPV. Differentiated PeIN is HPV-negative, p16-negative, and frequently harbors TP53 mutations and 9p21/CDKN2A loss; it tends to behave more aggressively.

04Dermoscopic features of PeIN were systematically described by Chan et al. (Australas J Dermatol 2019) in 11 histopathologically confirmed cases. Across all variants the most consistent signs were structureless areas (100 percent of cases, pink in 72.7 percent), vascular structures (81.8 percent, predominantly clustered dotted vessels in 72.7 percent, with glomerular vessels in a further 27.3 percent), and absence of a true pigment network (100 percent). Other findings included scale (45.5 percent), scar-like areas (45.5 percent), erosions (27.3 percent), and brown-grey dots and globules in 27.3 percent (mostly Bowenoid papulosis and pigmented Bowen disease).

05Variant-specific dermoscopy is helpful. Bowenoid papulosis shows brown-grey dots and globules in a linear peripheral arrangement, may include crown vessels, and is often pigmented. Bowen disease of the penis (when non-pigmented) shows pink or skin-coloured structureless areas with clustered dotted or glomerular vessels, scale, and scar-like areas; pigmented Bowen disease adds brown to grey dots and granules in linear distribution. Erythroplasia of Queyrat is the purest mucosal pattern: pink structureless areas plus clustered dotted or glomerular vessels, often with erosion (60 percent of cases) and without pigmentation. Polymorphic vessel patterns (dotted plus glomerular plus linear or comma) and a sharp demarcation favor PeIN over inflammatory mimics.

06The clinical differential includes Zoon balanitis (orange-yellow background but with curved (focal) vessels and parallel orange-red structureless zones), lichen sclerosus (white-pink atrophic plaques with linear or branched vessels and absent dotted vessel clusters), lichen planus (Wickham striae, violaceous color, linear vessels), psoriasis (regular dotted vessels uniformly distributed, white scale), genital warts (papillary projections with central looped vessels), candidiasis, and fixed drug eruption. Up to 90 percent of PeIN patients have a coexisting genital dermatosis, making baseline pattern recognition essential.

07Management follows the WHO/NCCN/EAU-ASCO framework with organ-preservation as the goal in early disease. Topical 5-fluorouracil and topical imiquimod are accepted first-line non-invasive options; ablative CO2 or Er:YAG laser, cryotherapy, photodynamic therapy, and circumcision (for foreskin disease) are alternatives. Surgical excision, glans resurfacing, or glansectomy are reserved for extensive, recurrent, or treatment-refractory disease. p16-positive lesions in a 137-patient European cohort (Ashley et al., 2021) showed longer disease-free survival on imiquimod, 5-fluorouracil, or surgery regardless of modality.

08Risk of progression to invasive penile SCC is up to 30 percent if untreated, underscoring the value of dermoscopy-guided biopsy and ongoing surveillance. The largest meta-analysis to date (Mustasam et al., JNCCN 2025; 34 studies, 3,994 patients) confirmed that p16-positivity in invasive penile SCC predicts substantially better disease-specific survival (HR 0.34), overall survival (HR 0.54), and disease-free survival (HR 0.52); HPV DNA positivity correlated with improved DFS (HR 0.63) and DSS (HR 0.46). HPV-independent (differentiated) disease behaves more aggressively. Adjunctive imaging at the bedside (reflectance confocal microscopy and optical coherence tomography) can map mucosal lesions, define margins, and reduce unnecessary biopsies, although these tools remain research-stage in most centres.

Key dermoscopic features

Pink structureless areas
Cardinal dermoscopic sign of PeIN, present in 72.7 percent of cases overall and 100 percent of erythroplasia of Queyrat. Reflects orange-pink mucosal background with loss of normal architecture.Diffuse, sharply demarcated zones of homogeneous pink color without follicular openings or true network.
Clustered dotted vessels
Most common vascular finding (72.7 percent of cases); clustering rather than uniform distribution distinguishes PeIN from psoriasis.Pinpoint red dots aggregated in focal clusters rather than evenly spread; visible at 10x magnification with non-contact dermoscopy.
Glomerular vessels
Coiled glomeruloid capillaries seen in 27.3 percent of cases, often co-existing with dotted vessels in a polymorphic pattern. Highly characteristic of in-situ SCC at any anatomic site.Slightly larger, twisted, kidney-glomerulus-like vessels arranged in clusters or lines.
Polymorphic vascular pattern
Combination of two or more vessel morphologies (dotted, glomerular, linear, crown, comma) seen in 63.6 percent of PeIN cases. Suggests a neoplastic vascular response.Dotted plus glomerular is the most common pair; addition of crown or comma vessels broadens the differential to other genital pathology.
Absence of true pigment network
Universal in mucosal PeIN (100 percent of cases). Helps separate PeIN on glans/sulcus from melanocytic lesions and from the parallel-ridge pattern of acral pigmentation.No reticulate brown lines; if pigmentation is present it is in dots and globules, not network.
Brown-grey dots and globules in linear (peripheral) arrangement
Pigmentation hallmark of Bowenoid papulosis and pigmented Bowen disease; correlates histologically with melanin in atypical keratinocytes plus dermal melanophages.Small dots and granules aligned along the lesion border, sometimes mosaic centrally.
White or skin-coloured structureless areas with white lines
Seen in a subset (about 18 percent of cases), often Bowenoid papulosis on shaft or hyperkeratotic Bowen disease.Bright structureless white zones, sometimes with chrysalis-like white shiny lines on polarized dermoscopy.
Scar-like areas
Present in 45.5 percent overall, more common in Bowen disease (75 percent of cases). Histologically corresponds to fibrosis in lamina propria.Pale, ivory-white homogeneous patches with loss of vessels.
Surface scale
Marker of keratinized-epithelium variants (Bowen disease 75 percent, erythroplasia of Queyrat 40 percent, never seen in Bowenoid papulosis cohort here). Helps distinguish keratinized shaft disease from glabrous mucosa.White or yellowish flakes, sometimes with serous crust.
Erosion
Hallmark of erythroplasia of Queyrat (60 percent of EQ cases). Should always raise concern for early invasive disease and prompt biopsy.Glistening, denuded red surface, sometimes with serous exudate; clustered glomerular vessels often visible at the rim.
Crown vessels
Less specific finding, also seen in sebaceous hyperplasia and molluscum; in PeIN they appear in 27 percent and indicate vascular ectasia at the lesion edge.Linear, telangiectatic vessels radiating peripherally without crossing the centre.
Sharp demarcation against normal mucosa
Useful clue when paired with clustered dotted/glomerular vessels; helps separate PeIN from Zoon balanitis (typically less sharply outlined) and lichen planus.Abrupt change from pink structureless zone to surrounding normal pink mucosa, often best appreciated with polarized light.

High yield clinical points15 pearls in 5 groups

Recognition & pattern analysis

7 points
1
Pink structureless background plus clustered dotted vessels is the dermoscopic core. Chan et al. found pink structureless areas in 72.7 percent and dotted vessels in 72.7 percent of PeIN cases, with absence of true pigment network in 100 percent.
2
Polymorphic vessel pattern raises suspicion. Two or more vessel morphologies (dotted, glomerular, linear, crown, comma) in one lesion are present in 63.6 percent of PeIN. A monomorphic uniformly dotted pattern argues for psoriasis.
3
Mucosal site changes the dermoscopic baseline. On the glans and inner prepuce, expect an orange-pink mucosal background rather than the network-rich epidermis seen on shaft skin. Loss of this homogeneous background and emergence of structureless pink with clustered vessels is the in-situ signal.
4
Pigmented PeIN exists and is dermoscopically distinctive. Brown-grey dots and globules in a linear peripheral arrangement is the hallmark of Bowenoid papulosis and pigmented Bowen disease (about 27 percent of cases). True pigment network is still absent.
5
p16 may matter more than HPV DNA. In the JNCCN meta-analysis, p16 positivity correlated with improved overall survival (HR 0.54) while HPV DNA alone did not (HR 0.91). p16 captures transcriptionally active virus rather than incidental DNA.
6
Lichen sclerosus on the glans is a red flag for differentiated PeIN. About a third of patients in the Chan dermoscopy series had concurrent lichen sclerosus. These are HPV-negative, p16-negative lesions that are clinically subtle and often have only ill-defined erythema with linear branched vessels rather than the classic dotted-cluster pattern.
7
HPV vaccination is the upstream play. Gardasil-9 covers HR-HPV 16 and 18, which together drive 46 to 62 percent of HPV-associated penile cancers. ACIP recommends HPV vaccination for all adolescents starting at age 11 to 12, catch-up through age 26, with shared clinical decision-making for adults 27 to 45.

Management & treatment

2 points
1
Treat early, conservatively when possible. Topical 5-FU and imiquimod are first-line for PeIN; CO2 laser, cryotherapy, and circumcision for foreskin disease are alternatives. Reserve glans resurfacing and glansectomy for refractory or extensive cases. p16-positive lesions respond well across modalities.
2
Imaging adjuncts can extend the exam. Reflectance confocal microscopy and optical coherence tomography map mucosal architecture in real time, can assist in margin delineation before topical therapy or surgery, and may reduce repeat biopsies in surveillance. Both remain research-stage in most centres.

Pitfalls & mimics

3 points
1
Erosion in a glans plaque means biopsy now. Erosion is present in 60 percent of erythroplasia of Queyrat cases and was associated with focal early invasive SCC in the Chan series. Do not chalk it up to friction or balanitis.
2
Don't confuse Zoon balanitis with erythroplasia of Queyrat. Zoon shows a gold-orange background with focal vessels and parallel orange-red structureless zones. EQ shows pink structureless zones with clustered dotted/glomerular vessels and frequent erosion. When in doubt, biopsy.
3
Use dermoscopy to choose the biopsy site. Within a heterogeneous plaque, the area with the most prominent clustered glomerular vessels, scale, or erosion is the most likely yield site for SCC in-situ or focal invasion. Avoid sampling only the homogeneous pink margin.

Follow-up & monitoring

1 point
1
Risk of progression up to 30 percent. Untreated PeIN can transform to invasive penile SCC in roughly a third of cases over time. Lifelong follow-up is recommended; over 80 percent of patients in the Chan series had a prior history of PeIN.

Recent changes (2022 onward)

2 points
1
WHO 2022 reorganizes PeIN by HPV pathway. Subtype as HPV-associated (basaloid, warty, mixed warty-basaloid) or HPV-independent (differentiated). Differentiated PeIN is the lichen sclerosus-associated, p16-negative variant and tends to behave most aggressively.
2
Order p16(INK4a) IHC on every penile SCC and PeIN biopsy. Mandatory under EAU-ASCO 2023. p16 IHC is the standard surrogate for transcriptionally active HPV with high specificity (though not absolute, since some p16-positive cases are HPV DNA-negative) and predicts better DSS (HR 0.34), OS (HR 0.54), and DFS (HR 0.52) in the largest meta-analysis to date (Mustasam et al., JNCCN 2025).

Notable updates & conceptual milestones5 updates

WHO 2022 etiology-based reclassification

2022-2023

The 2022 WHO Blue Book on urinary and male genital tumours reorganized penile carcinomas and PeIN around HPV status, replacing the older usual/basaloid/warty schema with HPV-associated (basaloid, warty, mixed warty-basaloid) and HPV-independent (differentiated) categories. The 2023 EAU-ASCO update made reporting of p16(INK4a) status mandatory on every penile SCC pathology report.

First systematic dermoscopy series of PeIN

2019

Chan et al. (Australasian Journal of Dermatology, 2019) reported the first dedicated dermoscopic case series across all three classical variants (Bowenoid papulosis, Bowen disease, erythroplasia of Queyrat), establishing pink structureless areas, clustered dotted and glomerular vessels, and absent pigment network as the diagnostic triad and providing variant-specific signatures.

Largest meta-analysis on p16 prognostic value in PSCC

2025

Mustasam et al. (JNCCN 2025) pooled 34 studies and 3,994 patients. p16-positivity predicted improved DSS (HR 0.34), OS (HR 0.54), and DFS (HR 0.52). HPV DNA positivity alone showed weaker effects. The authors recommend universal p16 IHC in penile SCC workup, supporting NCCN and EAU-ASCO guidelines.

Targeted and immune therapies for HPV-associated penile SCC

2024-2025

Multiple active trials are testing E6/E7 TCR-T cells (NCT05639972), HPV peptide and DNA vaccines (PRGN-2009, MEDI0457, IBRX-042), oncolytic virus vaccines, anti-PD-1/PD-L1 combinations, and the Nectin-4 antibody-drug conjugate enfortumab vedotin (case-level activity reported in metastatic PSCC). HPV-associated tumors show better response rates to anti-PD-1 combinations than HPV-independent tumors.

Topical and organ-preserving therapy data for PeIN

2021-2024

An eUROGEN study of 137 patients (Ashley et al., 2021) showed that p16-positive PeIN had significantly longer disease-free survival across imiquimod, 5-fluorouracil, or surgical treatment, supporting non-invasive first-line management in selected cases. NCCN Penile Cancer 2024 endorses 5-FU, imiquimod, ablative laser, cryotherapy, and circumcision as accepted alternatives to surgery for PeIN.

Bottom line

Mucosal in-situ SCC of the penis. HPV-driven and HPV-independent pathways with distinct clinical and dermoscopic signatures.

15 clinical points · 5 recent updates · 9 references

References

Sources cited in the lecture content or that underpin the clinical points above. Verify with primary sources before practice changes.

  1. [1]
    Chan SL, Watchorn RE, Panagou E, et al. Dermatoscopic findings of penile intraepithelial neoplasia: Bowenoid papulosis, Bowen disease and erythroplasia of Queyrat. Australas J Dermatol. 2019;60(3):e201-e207.
    PubMed: 30585302DOI: 10.1111/ajd.12981· First systematic dermoscopy series of 11 histopathologically confirmed PeIN cases. Established structureless pink areas, clustered dotted/glomerular vessels, and absence of pigment network as cardinal features. Variant-specific patterns also described.
  2. [2]
    Menon S, Moch H, Berney DM, et al. WHO 2022 Classification of Penile and Scrotal Cancers: Updates and Evolution. Histopathology. 2023;82(3):508-520.
    PubMed: 36221864DOI: 10.1111/his.14829· Authoritative summary of the 2022 WHO reclassification of penile carcinomas and PeIN into HPV-associated (basaloid, warty, mixed) and HPV-independent (differentiated) subtypes.
  3. [3]
    Moch H, Amin MB, Berney DM, et al. The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs - Part A: Renal, Penile, and Testicular Tumours. Eur Urol. 2022;82(5):458-468.
    PubMed: 35853783DOI: 10.1016/j.eururo.2022.06.016· Companion source for the 2022 WHO Blue Book penile section, used in the reclassification of PeIN subtypes and WHO recommendations on histologic reporting.
  4. [4]
    Mannam G, Miller JW, Johnson JS, Gullapalli K, Fazili A, Spiess PE, Chahoud J. HPV and Penile Cancer: Epidemiology, Risk Factors, and Clinical Insights. Pathogens. 2024;13(9):809.
    PubMed: 39339000DOI: 10.3390/pathogens13090809· Comprehensive review covering HPV-driven and HPV-independent penile carcinogenesis, risk factors, p16 prognostic value, tumor immune microenvironment, and emerging HPV-targeted therapies including TCR-T cells and therapeutic vaccines.
  5. [5]
    Mustasam A, Parza K, Ionescu F, et al. The Prognostic Role of HPV or p16(INK4a) Status in Penile Squamous Cell Carcinoma: A Meta-Analysis. J Natl Compr Canc Netw. 2025;23(2):e247078.
    PubMed: 39752880DOI: 10.6004/jnccn.2024.7078· Largest meta-analysis to date (34 studies, 3,994 patients). p16-positivity predicted improved DSS (HR 0.34), OS (HR 0.54), DFS (HR 0.52); HPV DNA improved DFS (HR 0.63) and DSS (HR 0.46). Supports universal p16 IHC at diagnosis.
  6. [6]
    Brouwer OR, Albersen M, Parnham A, et al. European Association of Urology-American Society of Clinical Oncology Collaborative Guideline on Penile Cancer: 2023 Update. Eur Urol. 2023;83(6):548-560.
    PubMed: 36906413DOI: 10.1016/j.eururo.2023.02.027· Made p16(INK4a) reporting mandatory on penile SCC pathology and outlined organ-preserving algorithms (5-FU, imiquimod, ablative laser, glans resurfacing) for early disease.
  7. [7]
    Ashley S, Shanks JH, Oliveira P, Lucky M, Parnham A, Lau M, Sangar V. Human Papilloma Virus (HPV) status may impact treatment outcomes in patients with pre-cancerous penile lesions (an eUROGEN Study). Int J Impot Res. 2021;33(6):620-626.
    PubMed: 32710000DOI: 10.1038/s41443-020-00366-8· European multicentre PeIN cohort (n=137) showing that p16-positive lesions had longer disease-free survival across imiquimod, 5-fluorouracil, and surgery, reinforcing organ-preservation in selected patients.
  8. [8]
    Olesen TB, Sand FL, Rasmussen CL, Albieri V, Toft BG, Norrild B, Munk C, Kjaer SK. Prevalence of human papillomavirus DNA and p16(INK4a) in penile cancer and penile intraepithelial neoplasia: a systematic review and meta-analysis. Lancet Oncol. 2019;20(1):145-158.
    PubMed: 30573285DOI: 10.1016/S1470-2045(18)30682-X· Pooled analysis showing HPV DNA in roughly 50 percent of penile SCC and over 80 percent of PeIN, with HPV 16 dominant. Supports the HPV-driven versus HPV-independent dichotomy now codified in WHO 2022.
  9. [9]
    Trias I, Algaba F, de Torres I, et al. p53 Immunohistochemistry Defines a Subset of HPV-Independent Penile SCCs With Adverse Prognosis. Am J Surg Pathol. 2024;48(11):1439-1447.
    PubMed: 39040011DOI: 10.1097/PAS.0000000000002291· Stratify PSCC and PeIN into HPV-associated, HPV-independent p53-normal (low risk), and HPV-independent p53-abnormal (27% disease-specific mortality vs 0% in p53-normal). Pattern-based p53 IHC standard alongside p16.